Drug discovery

#Clinical trial #Depression #Drug development #Drug discovery #Research

Magic mushroom compound performs as well as leading antidepressant

In a small study carried out by researchers at the Centre for Psychedelic Research at Imperial College London, it was found that psilocybin, the active compound in magic mushrooms, may be at least as effective as a leading antidepressant medication in a therapeutic setting. In a rigorous trial which assessed… Read More

#News

#Biopharma #Biotechnology #Covid-19 #Drug discovery #Laboratory data #Life sciences

From siloed to streamlined: Pharma data management is changing

Claire Hill, Head of Strategic Marketing at IDBS, explores ways in which the pharmaceutical sector can reap the benefits of an increasingly digital world. The Covid-19 pandemic pushed the process of drug development into the spotlight in a new way. The challenge for biopharmaceutical companies—to create, test, and manufacture a… Read More

#Exclusive Content #News #Opinion

#Antibiotics #Biomedical research #Drug discovery #Research

ANTRUK launches research grants programme for antibiotic resistance

Antibiotic Research UK (ANTRUK), a charity tackling bacterial antibiotic resistance, has launched its 2021 Small Research Grants / Career Development Awards scheme. This is the charity’s largest grants programme to date. The charity will be awarding one grant of up to £50,000 and six grants of up to £25,000 each. Read More

#News

#Biopharmaceutical #Biotechnology #Drug development #Drug discovery #Life sciences

Evotec collaborates with Bristol Myers Squibb to advance therapeutics

Evotec has launched beLAB2122, a US$20 million BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaboration with Bristol-Myers Squibb. beLAB2122 brings together academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and… Read More

#News

#Biologics / Biotechnology #Biopharmaceutical #Drug development #Drug discovery #Life sciences

Investment helps establish animal alternative skin testing technology

A near-£1 million investment will help University of Dundee spinout company Ten Bio to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. The investment will enable the company to progress its mission to transform the testing of new… Read More

#News

#Drug development #Drug discovery #Flow Cytometry #Miltenyi Biotec #Narrated podcasts

Flow Cytometry in Drug Discovery

This narrated article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at Miltenyi Biotec, outlines the benefits of flow cytometry, offering case study examples for its use. Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, it’s time for… Read More

#Podcasts

Cytometry
#Biologics / Biotechnology #Biotechnology #Drug development #Drug discovery #Flow Cytometry #High throughput screening #Podcast

DDW podcast: Flow cytometry in drug discovery

The latest free to listen to DDW podcast episode, titled Flow Cytometry in Drug Discovery, covers an article written by Urmi Roy for DDW, read aloud by Megan Thomas. This article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at… Read More

#News

#Cancer #Cancer research #Clinical trial #Drug development #Drug discovery

Virus therapy shows promise against inoperable skin cancers

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a… Read More

#Cancer Research #News

#AI #AI / data analytics / healthtech / informatics #Cancer research #Drug design #Drug development #Drug discovery

First AI-designed immuno-oncology drug enters clinical trials

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More

#Cancer Research #News

#Cancer research #DNA #Drug delivery #Drug development #Drug discovery

Blocking a protein may overcome cancer resistance to PARP inhibitors

Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More

#Cancer Research #Editor's Choice #News

#Biomedical research #Drug discovery #iPSC #Synthetic biology

Sitting down with…bit.bio

bit.bio is a synthetic biology company working on producing every human cell type at scale, with the aim of transforming the research and medicine landscape. Farah Patell-Socha, PhD, VP Research Products tells Lu Rahman about some of the company’s groundbreaking work in this field and the benefits it is creating… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Drug discovery #Research

Charles River and Valence partner to provide AI-enabled drug design

Charles River Laboratories and Valence Discovery have teamed up to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimisation. Building on research done by Valence’s founding team at Mila, a deep learning research institute, the Valence platform enables the design of small… Read More

#News

#Drug development #Drug discovery #Generics #Pharmaceuticals

Drug discovery and India: the future looks bright

As the world’s largest generic producer how far advanced is India’s drug discovery push and where does it stand on the global stage? Lu Rahman explores. India has become a key player in the global pharmaceutical sector. The value of its part in this industry is expected to reach $120… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Intelligence #Market Reports #News

#Biotherapeutics #Drug development #Drug discovery #Novel therapeutics

Infex’s resistance bypass drug program ready for clinic

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More

#News

#CRISPR #Drug discovery #Liquid handling #Synthetic biology

Expert advice: maintaining lab flow throughout the pandemic

Lu Rahman talks to John Fuller, Product Manager–Drug Discovery, Beckman Coulter Life Sciences about the pandemic’s impact on this global organisation and its customers — and what to expect in 2021 and beyond. Not surprisingly, the emergence of the Covid-19 pandemic in 2020 caused hundreds, if not thousands of… Read More

#Exclusive Content #News #Opinion

#Biotechnology #Drug discovery #Genetics / genomes #Genetics / genomics #Research

Francis Crick Institute and GSK to pioneer reactive fragment screening

Researchers at the Francis Crick Institute and GSK are extending their collaboration to advance the discovery of new drug targets in a £11.5 million effort. This comes after receiving a ‘Prosperity Partnership’ grant from the Engineering and Physical Sciences Research Council (EPSRC) and matching funds from GSK. Together, the teams… Read More

#News